期刊文献+

地西他滨联合丙戊酸钠对AML细胞株U937促凋亡和分化的影响

Synergistic effect of decitabine and valproic acid on induction of apoptosis and differentiation in leukemic U937 cells
原文传递
导出
摘要 目的:探讨地西他滨(decitabine,DCA)和丙戊酸钠(valproic acid,VPA)联用对白血病细胞株U937的促凋亡和分化影响。方法:设立分组如下:对照组,DCA单药A组(1.0μmol/L),DCA单药B组(4.0μmol/L),VPA单药组(2.0 mmol/L),联合用药A组(DCA 1.0μmol/L+VPA 2.0 mmol/L),联合用药B组(DCA 4.0μmol/L+VPA 2.0 mmol/L),作用48 h。应用Annexin V-FITC/PI标记法检测早期凋亡率,流式细胞术检测CD34、CD117 MFI以及CD11b、CD14表达率。结果:联合用药组A、B的凋亡率高于其各自的单药组,差异具有显著统计学意义(P<0.01);联合用药A、B组的CD117和CD34 MFI低于其各自的单药组,差异具有显著统计学意义(P<0.01);联合用药A、B组的CD11b和CD14表达率低于其各自的单药组,差异具有显著统计学意义(P<0.01)。结论:U937细胞中VPA能显著增强DCA的促凋亡分化作用。 Objective:To investigate the synergistic effect of decitabine(DCA) and valproic acid(VPA) in apoptosis and differentiation induction in leukemic U937 cells.Methods: The drug groups were set as follows:control group;DCA alone group A(1.0 μmol/L);DCA alone group B(4.0 μmol/L);VPA alone group(2.0 mmol/L);combination group A(DCA 1.0 μmol/L+VPA 2.0 mmol/L);combination group B(DCA 4.0 μmol/L+VPA 2.0 mmol/L).The cells were treated by drug for 48 hours.The early apoptosis rates were detected by staining with Annexin V and PI.The CD117,CD34 mean fluorescence intensity(MFI) and CD14,CD11b expression were detected by flow cytometry.Results: The apoptosis rates of combination group A and B were significantly higher than their corresponding concentration single drug group(P0.01).The CD117,CD34 MFI of combination group A and B were significantly lower than their corresponding concentration single drug group(P0.01).The CD14,CD11b expressions of combination group A and B were significantly lower than their corresponding concentration single drug group(P0.01).Conclusion: There was an enhanced antileukemia activity of combinations of DCA and VPA on apoptosis and differentiation of U937 cells.
出处 《中国卫生检验杂志》 北大核心 2012年第11期2625-2627,共3页 Chinese Journal of Health Laboratory Technology
关键词 分化抗原 凋亡 U937细胞 丙戊酸钠 地西他滨 Differntiation antigen Apoptosis U937 Valproic acid Decitabine
  • 相关文献

参考文献13

  • 1Lubbert M, Sueiu S, Baila L, et al. Low - dose decitabine versus best supportive care in elderly patients with intermediate - or high - risk myelodysplastie syndrome (MDS) ineligible for intensive chemothera- py : final results of the randomized phase III study of the European Or- ganization for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group [ J ]. J Clin Oncol, 2011, 29 (15): 1987 - 1996.
  • 2Santos FP, Kantarjian H, Garcia - Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes [ J ]. Expert Rev Anticancer T- her, 2010, 10(1) : 9 -22.
  • 3Cui W, Sun J, Cotta CV, et al. Myelodysplastic Syndrome With inv ( 3 ) ( q21 q26.2 ) or t ( 3 ; 3 ) ( q21 ; q26.2 ) Has a High Risk for Pro- gression to Acute Myeloid Leukemia[J]. Am J Clin Pathol, 2011, 136(2) :282 -288.
  • 4Blum W,Klisovic RB, Hackanson B,et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia [J]. J Clin Oncol,2007,25 (25) :3884 - 3891.
  • 5Manev H, Uz T. DNA hypomethylating agents 5 - aza - 2' - deoxycyti- dine and valproate increase neuronal 5 -lipoxygenase mRNA[ J]. Eur J Pharmacol, 2002, 445( 1 -2) : 149 - 150.
  • 6Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethyla- tion and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication [J]. Blood, 2008. 112(5): 2013 -2016.
  • 7Daskalakis M, Blagitko - Dorfs N, Hackanson B. Decitabine [ J ]. Re- cent Results Cancer Res, 2010, 184 ( 11 ) : 131 - 157.
  • 8Brodska B, Otevrelova P,Holoubek A. Decitabine- induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA[J]. Mol Cell Biochem, 2011. 350(1 -2) : 71 -80.
  • 9Candelaria M, Hen'era A, Labardini J,et al. Hydralazine and magnesi- um valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase - II trial [ J ]. Ann Hematol, 2011, 90 (4) : 379 -387.
  • 10Yang H, Hoshino K, Sanchez - Gonzalez B, et al. Antileukemia activi- ty of the combination of 5 - aza - 2' - deoxycytidine with valproic acid. Leuk Res, 2005. 29(7) : 739 -748.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部